FilingReader Intelligence

Aurobindo subsidiary gains UK approval for biosimilar Dazublys

August 26, 2025 at 04:19 AM UTC•By FilingReader AI

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, received UK MHRA marketing authorization for Dazublys, its trastuzumab biosimilar. This follows European Union approval in July 2025.

Dazublys is CuraTeQ's fourth biosimilar approved by MHRA, alongside Bevqolva, Zefylti, and Dyrupeg.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

Intimation of receipt approval for biosimilar Dazyblys from UK''s MHRA by Curateq Biologics s.r.o a wholly owned step-down subsidiary of the Company.August 26, 2025 at 04:10 AM UTC

Aurobindo Pharma

BSE:AUROPHARMA•Bombay Stock Exchange

RSS feed for Aurobindo Pharma

News Alerts

Get instant email alerts when Aurobindo Pharma publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →